Table 5. The effect of cardiac protective agents on cardiac toxicity.
| Variable | Subvariable | Total (n=78) N (%) | Outcome cardiac toxicity | Univariate analysis | P-value | |
| No n (%) 66(84.6) | Yes n (%) 12(15.4) | OR (95 % CI) | ||||
| Use of cardio-protective drugs | No | 62(79.5) | 54(87.1) | 8(12.9) | 0.44 (0.11 to 1.72) | 0.240 |
| Yes | 16(20.5) | 12(75.0) | 4(25.0) | Reference group | ||
| Beta-blocker | No | 68(87.2) | 59(86.8) | 9(13.2) | 0.35 (0.07 to 1.63) | 0.184 |
| Yes | 10(12.8) | 7(70.0) | 3(30.0) | Reference group | ||
| ACE inhibitors | No | 63(80.8) | 55(87.3) | 8(12.7) | 0.40 (0.10 to 1.56) | 0.188 |
| Yes | 15(19.2) | 11(73.3) | 4(26.7) | Reference group | ||
| Statins | No | 64(82.1) | 57(89.1) | 7(10.9) | 0.22 (0.05 to 0.84) | 0.028 |
| Yes | 14(17.9) | 9(64.3) | 5(35.7) | Reference group | ||
| Antiplatelets | No | 71(91.0) | 62(87.3) | 9(12.7) | 0.19 (0.03 to 1.01) | 0.051 |
| Yes | 7(9.0) | 4(57.1) | 3(42.9) | Reference group | ||